EMEA-000170-PIP03-13-M04 - paediatric investigation plan

Eltrombopag
PIPHuman

Key facts

Invented name
Revolade
Active Substance
Eltrombopag
Therapeutic area
Haematology-Hemostaseology
Decision number
P/0516/2020
PIP number
EMEA-000170-PIP03-13-M04
Pharmaceutical form(s)
  • Film-coated tablet
  • Powder for oral suspension
Condition(s) / indication(s)
Treatment of aplastic anaemia
Route(s) of administration
Oral use
Contact for public enquiries

Novartis Europharm Limited
E-mail: paediatric.enquiries@novartis.com
Tel. +41 613241111

Decision type
PM: decision on the application for modification of an agreed PIP
Decision date

Decision

Share this page